Experienced in Acromicric Dysplasia

Dr. Ian F. Pollack

Neurosurgery
3705 5th Ave, Chp, Room 3705, 
Pittsburgh, PA 
Experienced in Acromicric Dysplasia
3705 5th Ave, Chp, Room 3705, 
Pittsburgh, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ian Pollack is a Neurosurgery provider in Pittsburgh, Pennsylvania. Dr. Pollack is rated as an Experienced provider by MediFind in the treatment of Acromicric Dysplasia. His top areas of expertise are Glioma, Gliomatosis Cerebri, Brain Tumor, Posterior Fossa Decompression, and Craniectomy.

His clinical research consists of co-authoring 219 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Acromicric Dysplasia.

Specialties
Neurosurgery
Licenses
Specialist in PA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

3705 5th Ave, Chp, Room 3705, Pittsburgh, PA 15213

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug
Study Drug: Selumetinib
Study Phase: Phase 1/Phase 2
A Phase I Study of the Adam-10 Inhibitor, INCB7839 in Children With Recurrent/Progressive High-Grade Gliomas to Target Microenvironmental Neuroligin-3
A Phase I Study of the Adam-10 Inhibitor, INCB7839 in Children With Recurrent/Progressive High-Grade Gliomas to Target Microenvironmental Neuroligin-3
Enrollment Status: Completed
Publish Date: January 05, 2026
Intervention Type: Drug
Study Drug: INCB7839
Study Phase: Phase 1
Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects With Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma
Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects With Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Biological
Study Drug: APX005M
Study Phase: Phase 1
Feasibility Trial of Optune for Children With Recurrent or Progressive Supratentorial High-Grade Glioma or Ependymoma, and Feasibility and Efficacy Trial of Optune in Conjunction With Radiation Therapy for Children With Newly Diagnosed DIPG
Feasibility Trial of Optune for Children With Recurrent or Progressive Supratentorial High-Grade Glioma or Ependymoma, and Feasibility and Efficacy Trial of Optune in Conjunction With Radiation Therapy for Children With Newly Diagnosed DIPG
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2025
Intervention Type: Device, Combination product
Study Phase: Not Applicable
A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma, and CNS Tumors Harboring MET Aberrations
A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma, and CNS Tumors Harboring MET Aberrations
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Procedure, Drug
Study Drug: Savolitinib
Study Phase: Phase 1
A Phase I and Surgical Study of Ribociclib and Everolimus (RAD001) in Children With Recurrent or Refractory Malignant Brain Tumors
A Phase I and Surgical Study of Ribociclib and Everolimus (RAD001) in Children With Recurrent or Refractory Malignant Brain Tumors
Enrollment Status: Completed
Publish Date: August 27, 2021
Intervention Type: Other, Drug
Study Phase: Phase 1
Phase I Study of CDK 4-6 Inhibitor PD-0332991 (Palbociclib; IBRANCE) in Children With Recurrent, Progressive or Refractory Central Nervous System Tumors
Phase I Study of CDK 4-6 Inhibitor PD-0332991 (Palbociclib; IBRANCE) in Children With Recurrent, Progressive or Refractory Central Nervous System Tumors
Enrollment Status: Terminated
Publish Date: March 02, 2021
Intervention Type: Other, Drug
Study Phase: Phase 1
Phase II Study of Peginterferon Alfa-2b (Sylatron) for Pediatric Patients With Unresectable or Recurrent Craniopharyngioma
Phase II Study of Peginterferon Alfa-2b (Sylatron) for Pediatric Patients With Unresectable or Recurrent Craniopharyngioma
Enrollment Status: Terminated
Publish Date: February 24, 2020
Intervention Type: Other, Biological
Study Phase: Phase 2
View 7 Less Clinical Trials

218 Total Publications

Midlife ICAM-1 levels may predict cardiovascular disease and cognitive decline in latelife: Insights from the HeartSCORE study.
Midlife ICAM-1 levels may predict cardiovascular disease and cognitive decline in latelife: Insights from the HeartSCORE study.
Journal: Atherosclerosis plus
Published: July 17, 2025
Similar Doctors
Experienced in Acromicric Dysplasia
Dr. Cara L. Sedney
Neurosurgery
Experienced in Acromicric Dysplasia
Dr. Cara L. Sedney
Neurosurgery

West Virginia University Medical Corporation

1 Medical Ctr Dr, 
Morgantown, WV 
 (54.4 miles away)
304-598-4865
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Cara Sedney is a Neurosurgery provider in Morgantown, West Virginia. Dr. Sedney is rated as an Advanced provider by MediFind in the treatment of Acromicric Dysplasia. Her top areas of expertise are Stroke, Spinal Cord Abscess, Subdural Hematoma, Spinal Fusion, and Laminectomy. Dr. Sedney is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pollack's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 10 Advanced Conditions
View All 18 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile